ATE375153T1 - Verwendung von epoxydhydrolasekomplexe zur behandlung von hypertension - Google Patents
Verwendung von epoxydhydrolasekomplexe zur behandlung von hypertensionInfo
- Publication number
- ATE375153T1 ATE375153T1 AT00911767T AT00911767T ATE375153T1 AT E375153 T1 ATE375153 T1 AT E375153T1 AT 00911767 T AT00911767 T AT 00911767T AT 00911767 T AT00911767 T AT 00911767T AT E375153 T1 ATE375153 T1 AT E375153T1
- Authority
- AT
- Austria
- Prior art keywords
- sulfur
- oxygen
- hydrogen
- nitrogen
- epoxydhydrolase
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/252,148 US6150415A (en) | 1996-08-13 | 1999-02-18 | Epoxide hydrolase complexes and methods therewith |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE375153T1 true ATE375153T1 (de) | 2007-10-15 |
Family
ID=22954799
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT00911767T ATE375153T1 (de) | 1999-02-18 | 2000-02-10 | Verwendung von epoxydhydrolasekomplexe zur behandlung von hypertension |
Country Status (10)
Country | Link |
---|---|
US (1) | US6150415A (de) |
EP (2) | EP1154764B1 (de) |
JP (1) | JP2002540767A (de) |
AT (1) | ATE375153T1 (de) |
AU (1) | AU3360800A (de) |
CA (1) | CA2362331C (de) |
DE (1) | DE60036690T2 (de) |
DK (1) | DK1154764T3 (de) |
ES (1) | ES2291196T3 (de) |
WO (1) | WO2000048593A1 (de) |
Families Citing this family (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6150415A (en) * | 1996-08-13 | 2000-11-21 | The Regents Of The University Of California | Epoxide hydrolase complexes and methods therewith |
US8815951B2 (en) * | 1996-08-13 | 2014-08-26 | The Regents Of The University Of California | Inhibitors of epoxide hydrolases for the treatment of inflammation |
WO2000042012A1 (en) * | 1999-01-13 | 2000-07-20 | Bayer Corporation | φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS |
EP1158985B1 (de) | 1999-01-13 | 2011-12-28 | Bayer HealthCare LLC | GAMMA CARBOXYARYLSUBSTITUIERTE DIPHENYLHARNSTOFFVERBINDUNGEN ALS p38 KINASEHEMMER |
US7928239B2 (en) | 1999-01-13 | 2011-04-19 | Bayer Healthcare Llc | Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas |
US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
US6831099B1 (en) * | 1999-05-12 | 2004-12-14 | Yale University | Enzyme inhibition |
ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
US6562563B1 (en) * | 1999-11-03 | 2003-05-13 | Mitokor | Compositions and mehtods for determining interactions of mitochondrial components, and for identifying agents that alter such interactions |
US7235576B1 (en) | 2001-01-12 | 2007-06-26 | Bayer Pharmaceuticals Corporation | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
US6794158B2 (en) * | 2001-04-09 | 2004-09-21 | Boehringer Ingelheim Pharmaceuticals, Inc. | Fluorescence polarization assay |
US6756210B2 (en) * | 2001-05-29 | 2004-06-29 | The Regents Of The University Of California | Linoleic acid diol and glucuronide conjugate levels as diagnostic markers of disorders of abnormal regulation of cytochrome P450 metabolism of unsaturated fatty acids |
US6943001B2 (en) * | 2001-08-03 | 2005-09-13 | Diversa Corporation | Epoxide hydrolases, nucleic acids encoding them and methods for making and using them |
EP1578987A2 (de) * | 2001-08-03 | 2005-09-28 | Diversa Corporation | Epoxidhydrolasen, diese codierende nukleinsäuren sowie verfahren zu deren herstellung und verwendung |
US20030139469A1 (en) * | 2002-01-23 | 2003-07-24 | The Regents Of The University Of California | Use of inhibitors of soluble epoxide hydrolase to inhibit vascular smooth muscle cell proliferation |
PT1478358E (pt) | 2002-02-11 | 2013-09-11 | Bayer Healthcare Llc | Tosilato de sorafenib para o tratamento de doenças caracterizadas por angiogénese anormal |
US20030216396A1 (en) | 2002-02-11 | 2003-11-20 | Bayer Corporation | Pyridine, quinoline, and isoquinoline N-oxides as kinase inhibitors |
AU2003209118A1 (en) | 2002-02-11 | 2003-09-04 | Bayer Pharmaceuticals Corporation | Aryl ureas as kinase inhibitors |
GB0214342D0 (en) * | 2002-06-21 | 2002-07-31 | Givaudan Sa | Insect repellents |
EA010267B1 (ru) | 2002-10-07 | 2008-06-30 | Те Риджентс Оф Те Юниверсити Оф Калифорния | Модуляция тревоги через блокаду гидролиза анандамида |
US7557129B2 (en) | 2003-02-28 | 2009-07-07 | Bayer Healthcare Llc | Cyanopyridine derivatives useful in the treatment of cancer and other disorders |
US20050164951A1 (en) * | 2003-04-03 | 2005-07-28 | The Regents Of The University Of California | Inhibitors for the soluble epoxide hydrolase |
US20050026844A1 (en) | 2003-04-03 | 2005-02-03 | Regents Of The University Of California | Inhibitors for the soluble epoxide hydrolase |
JP2007511203A (ja) | 2003-05-20 | 2007-05-10 | バイエル、ファーマシューテイカルズ、コーポレイション | キナーゼ阻害活性を有するジアリール尿素 |
DE602004010407T2 (de) | 2003-07-23 | 2008-10-16 | Bayer Pharmaceuticals Corp., West Haven | Fluorsubstituierter omega-carboxyaryldiphenylharnstoff zur behandlung und prävention von krankheiten und leiden |
CA2559665A1 (en) | 2004-03-16 | 2005-09-29 | The Regents Of The University Of California | Reducing nephropathy with inhibitors of soluble epoxide hydrolase and epoxyeicosanoids |
ES2257152B1 (es) * | 2004-05-31 | 2007-07-01 | Laboratorios Almirall S.A. | Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos. |
CA2584342C (en) * | 2004-10-20 | 2013-04-30 | The Regents Of The University Of California | Improved inhibitors for the soluble epoxide hydrolase |
JP2008540433A (ja) * | 2005-05-06 | 2008-11-20 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 可溶性エポキシドヒドロラーゼインヒビター及びその使用方法 |
CA2608243A1 (en) * | 2005-05-06 | 2006-11-16 | Boehringer Ingelheim International Gmbh | Acyl hydrazones for treating cardiovascular diseases |
US9119837B2 (en) * | 2005-08-19 | 2015-09-01 | The Regents Of The University Of California | Use of sEH inhibitors as analgesics |
WO2007044491A1 (en) * | 2005-10-07 | 2007-04-19 | Boehringer Ingelheim International Gmbh | N-substituted pyridinone or pyrimidinone compounds useful as soluble epoxide hydrolase inhibitors |
PL2623113T3 (pl) | 2005-11-09 | 2018-05-30 | Onyx Therapeutics, Inc. | Związek do hamowania enzymu |
WO2007079593A1 (en) * | 2006-01-13 | 2007-07-19 | Mcgill University | Novel melatonin ligands having antidepressant activity as well as sleep inducing properties |
WO2007106705A1 (en) * | 2006-03-10 | 2007-09-20 | Boehringer Ingelheim International Gmbh | Soluble epoxide hydrolase inhibitors and methods of using same |
TW200808723A (en) | 2006-03-13 | 2008-02-16 | Univ California | Conformationally restricted urea inhibitors of soluble epoxide hydrolase |
EP2484688B1 (de) | 2006-06-19 | 2016-06-08 | Onyx Therapeutics, Inc. | Peptidepoxyketone für proteasom-hemmung |
EP2124928A4 (de) * | 2006-12-15 | 2011-01-05 | Univ California | Verwendung von cis-epoxyeicosatriensäuren und hemmern von löslicher epoxid-hydrolase zur behandlung von erkrankungen, die durch pbr, cb2 und nk hervorgerufen werden |
JP2010513372A (ja) * | 2006-12-18 | 2010-04-30 | エフ.ホフマン−ラ ロシュ アーゲー | 可溶性エポキシドヒドロラーゼの阻害剤の新規な使用 |
US8455520B2 (en) * | 2007-07-17 | 2013-06-04 | Merck Sharp & Dohme Corp. | Soluble epoxide hydrolase inhibitors, compositions containing such compounds and methods of treatment |
US20110098322A1 (en) * | 2007-08-06 | 2011-04-28 | The Regents Of The University Of California | Preparation of novel 1,3-substituted ureas as inhibitors of soluble epoxide hydrolase |
US8367617B2 (en) | 2007-10-04 | 2013-02-05 | Onyx Therapeutics, Inc. | Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides |
EP2259680A4 (de) * | 2008-03-04 | 2012-01-25 | Merck Sharp & Dohme | Lösliche epoxidhydrolasehemmer, zusammensetzungen mit derartigen verbindungen und behandlungsverfahren damit |
EP2100598A1 (de) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalationszusammensetzung enthaltend Aclidinium zur Behandlung von Asthma sowie chronisch-obstruktiver Lungenerkrankung |
EP2100599A1 (de) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalationszusammensetzung enthaltend Aclidinium zur Behandlung von Asthma sowie chronisch-obstruktiver Lungenerkrankung |
EP3090737A1 (de) | 2008-10-21 | 2016-11-09 | Onyx Therapeutics, Inc. | Kombinationstherapie mit peptidepoxyketonen |
WO2010096722A1 (en) | 2009-02-20 | 2010-08-26 | Takeda Pharmaceutical Company Limited | 3-oxo-2, 3-dihydro- [1,2, 4] triazolo [4, 3-a]pyridines as soluble epoxide hydrolase (seh) inhibitors |
AR075899A1 (es) | 2009-03-20 | 2011-05-04 | Onyx Therapeutics Inc | Tripeptidos epoxicetonas cristalinos inhibidores de proteasa |
US8853147B2 (en) | 2009-11-13 | 2014-10-07 | Onyx Therapeutics, Inc. | Use of peptide epoxyketones for metastasis suppression |
US9296693B2 (en) | 2010-01-29 | 2016-03-29 | The Regents Of The University Of California | Acyl piperidine inhibitors of soluble epoxide hydrolase |
JP6042724B2 (ja) | 2010-03-01 | 2016-12-14 | オニキス セラピューティクス, インク.Onyx Therapeutics, Inc. | イムノプロテアソーム阻害のための化合物 |
EP2555621A4 (de) | 2010-04-07 | 2014-07-02 | Onyx Therapeutics Inc | Kristalliner peptid-epoxyketon-immunproteasomhemmer |
EP2389922A1 (de) | 2010-05-25 | 2011-11-30 | Symrise AG | Cyclohexylcarbamatverbindungen als Anti-ageing-Wirkstoffe |
WO2012112570A1 (en) | 2011-02-14 | 2012-08-23 | The Regents Of The University Of California | SORAFENIB DERIVATIVES AS sEH INHIBITORS |
EP2510928A1 (de) | 2011-04-15 | 2012-10-17 | Almirall, S.A. | Aclidinium zur Verbesserung der Schlafqualität bei atemwegserkrankten Patienten |
WO2013116690A1 (en) | 2012-02-01 | 2013-08-08 | The Regents Of The University Of California | Acyl piperidine inhibitors of soluble epoxide hydrolase |
WO2013138118A1 (en) | 2012-03-14 | 2013-09-19 | The Regents Of The University Of California | Treatment of inflammatory disorders in non-human mammals |
TW201414751A (zh) | 2012-07-09 | 2014-04-16 | 歐尼克斯治療公司 | 肽環氧酮蛋白酶抑制劑之前驅藥物 |
US10813894B2 (en) | 2015-02-20 | 2020-10-27 | The Regents Of The University Of California | Methods of inhibiting pain |
EP3463470A1 (de) | 2016-05-25 | 2019-04-10 | Johann Wolfgang Goethe-Universität Frankfurt am Main | Behandlung und diagnose von nichtproliferativer diabetischer retinopathie |
EP3863639A1 (de) | 2018-10-10 | 2021-08-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Verfahren und topische pharmazeutische zusammensetzungen zur behandlung der mikrovaskulären dysfunktion der haut |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1056290A (en) * | 1963-05-06 | 1967-01-25 | Du Pont | Dicycloalkyl ureas |
CA2017383A1 (en) * | 1989-06-08 | 1990-12-08 | Raymond R. Martodam | Use of vanilloids for the treatment of respiratory diseases or disorders |
AU636713B2 (en) * | 1990-02-26 | 1993-05-06 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of nitric oxide biosynthesis |
US5445956A (en) * | 1993-08-13 | 1995-08-29 | The Regents Of The University Of California | Recombinant soluble epoxide hydrolase |
US5599984A (en) * | 1994-01-21 | 1997-02-04 | The Picower Institute For Medical Research | Guanylhydrazones and their use to treat inflammatory conditions |
JP2909620B2 (ja) * | 1995-03-07 | 1999-06-23 | 参天製薬株式会社 | N,n−ジアルキルアミノフェニル基を有する新規アミノ酸誘導体 |
US6150415A (en) * | 1996-08-13 | 2000-11-21 | The Regents Of The University Of California | Epoxide hydrolase complexes and methods therewith |
US5955496A (en) * | 1996-08-13 | 1999-09-21 | The Regents Of The University Of California | Dihydroxy-oxy-eicosadienoates |
-
1999
- 1999-02-18 US US09/252,148 patent/US6150415A/en not_active Expired - Lifetime
-
2000
- 2000-02-10 WO PCT/US2000/003495 patent/WO2000048593A1/en active IP Right Grant
- 2000-02-10 EP EP00911767A patent/EP1154764B1/de not_active Expired - Lifetime
- 2000-02-10 JP JP2000599385A patent/JP2002540767A/ja active Pending
- 2000-02-10 AU AU33608/00A patent/AU3360800A/en not_active Abandoned
- 2000-02-10 DK DK00911767T patent/DK1154764T3/da active
- 2000-02-10 AT AT00911767T patent/ATE375153T1/de active
- 2000-02-10 CA CA2362331A patent/CA2362331C/en not_active Expired - Fee Related
- 2000-02-10 DE DE60036690T patent/DE60036690T2/de not_active Expired - Lifetime
- 2000-02-10 ES ES00911767T patent/ES2291196T3/es not_active Expired - Lifetime
- 2000-02-10 EP EP07014966A patent/EP1844767B1/de not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
DE60036690D1 (de) | 2007-11-22 |
ES2291196T3 (es) | 2008-03-01 |
WO2000048593A1 (en) | 2000-08-24 |
EP1154764A1 (de) | 2001-11-21 |
DE60036690T2 (de) | 2008-07-17 |
EP1844767A3 (de) | 2010-01-13 |
CA2362331A1 (en) | 2000-08-24 |
EP1844767B1 (de) | 2012-08-29 |
EP1154764B1 (de) | 2007-10-10 |
CA2362331C (en) | 2010-04-20 |
AU3360800A (en) | 2000-09-04 |
JP2002540767A (ja) | 2002-12-03 |
DK1154764T3 (da) | 2008-02-04 |
US6150415A (en) | 2000-11-21 |
EP1154764A4 (de) | 2005-02-16 |
EP1844767A2 (de) | 2007-10-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE375153T1 (de) | Verwendung von epoxydhydrolasekomplexe zur behandlung von hypertension | |
ATE202702T1 (de) | Verwendung von oestrogenagonisten und - antagonisten zur herstellung eines medikaments zur behandlung von atherosklerose, unabhängig von lipidsenkung | |
TR200402157T2 (tr) | Heteroaril süksinamidler ve metalloproteinaz inhibitörü olarak kullanımları | |
ES2196396T3 (es) | Compuestos heteroaromaticos de 5 miembros conteniendo oxigeno o azufre como inhibidores del factor xa. | |
DE69332792T2 (de) | 4,1-Benzoxazepinderivate als Squalen-Synthetase Inhibitoren und ihre Verwendung zur Behandlung von Hypercholesterämie und als Fungizide | |
DE68906183D1 (de) | 2'-desoxy-5-fluoruridinderivate. | |
ES2169150T3 (es) | Compuestos a base de dihidrobenzofurano y compuestos relacionados utiles como agentes anti-inflamatorios. | |
DE69911935D1 (de) | Granulatimide-derivate zur behandlung von krebs | |
PH19684A (en) | Biologically acitve heterocyclic compounds | |
DE69319764D1 (de) | Verfahren zur Herstellung von Beta-Lactamderivaten und Zwischenprodukt für ihre Synthese | |
DK1000034T3 (da) | Substituerede 6-alkylphenanthridiner | |
PL336857A1 (en) | Heterocyclic compounds, method of obtaining them and pharmaceutic composition containing such compounds | |
DE69910568D1 (de) | Furopyridinderivate und ihre therapeutische verwendung | |
BR9813923A (pt) | N n - bis(sulfonil) hidrazinas úteis como agentes antineoplásicos | |
MY121785A (en) | Hydroxamic acid derivatives as inhibitors of the production of soluble cd23 | |
BR9707321A (pt) | Dihidrobenzofurano e compostor correlatos úteis como agentes antinflamatórios | |
ATE147938T1 (de) | Inhibitoren der dihydrofolatreduktase von pneumocystis carinii | |
ATE255561T1 (de) | Verfahren und zusammensetzungen zur behandlung von leukämie | |
ES2121036T3 (es) | Derivados de alquilenodiamina. | |
BR0110328A (pt) | Compostos heterocìclicos com atividade antiinflamatória | |
EA200101058A1 (ru) | Ароматические амиды |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1154764 Country of ref document: EP |